Business
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflowsAdvancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026Strengthened IP footprint with new AI patent and 64 total issued and pending patents worldwideAnnounced $2.5 million share repurchase programStrong balance sheet, no debt and cash runway into the second half of 2027, reinforcing long-term growth strategy BROOMFIELD, Colo., April 30, 2026
About this update from Aclarion, Inc.
[{"type":"image","alt":"Aclarion, Inc.","displaySize":"","headline":null,"caption":"Aclarion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EohHW56rTadgndYE9QH9_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf","width":140,"height":83}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened IP footprint with new AI patent and 64 total issued and pending patents worldwide","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced $2.5 million share repurchase program","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong balance sheet, no debt and cash runway into the second half of 2027, reinforcing long-term growth strategy","length":113,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":465,"olType":false},{"type":"text","content":"BROOMFIELD, Colo., April 30, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today reported first quarter 2026 results highlighted by accelerating clinical adoption and strong execution across key strategic initiatives.","length":544,"tagName":"p"},{"type":"text","content":"Market Adoption Momentum","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Nociscan scan volumes increased 196% year-over-year (Q1 2026 vs. Q1 2025)","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"64% sequential scan volume growth (Q1 2026 vs. Q4 2025)","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Growth wa...